Combination Approaches for Metastatic Renal Cell Carcinoma - Episode 12

TKI/I-O Therapy in mRCC

EP. 1: Historical Perspectives on the Treatment of mRCC
EP. 2: Rationale for Combination Therapy in mRCC
EP. 3: Cabozantinib in mRCC
EP. 4: Nivolumab and Ipilimumab in mRCC
EP. 5: Bevacizumab and Interferon in mRCC
EP. 6: Antiangiogenic Resistance in mRCC
EP. 7: Making Decisions for Second-Line Therapy in mRCC
EP. 8: Second-Line Combination Therapy in mRCC
EP. 9: Lenvatinib and Everolimus in Relapsed/Refractory mRCC
EP. 10: Managing Patients on Lenvatinib/Everolimus in mRCC
EP. 11: Therapeutic Sequencing in mRCC
Now Viewing
EP. 12: TKI/I-O Therapy in mRCC
EP. 13: Emerging TKI/I-O Options in mRCC
EP. 14: Novel Combination Therapies Under Investigation in mRCC
EP. 15: PD-L1 Testing in mRCC
EP. 16: Future Directions for Research in mRCC

Transcript:

Related Content:

Combination Approaches for Metastatic Renal Cell CarcinomaGenitourinary Cancers
Dr Biachi on the Evolving Role for Surgery in CRC
Post Hoc Analysis Reveals Potential Serum Glycoproteomic Biomarkers for Nivolumab/Cabozantinib in Advanced RCC
Dr Singer on the Efficacy of IO/TKI Doublets in Advanced RCC